Multivariate joint modeling to identify markers of growth and lung function decline that predict cystic fibrosis pulmonary exacerbation onset by Andrinopoulou, E-R. (Eleni-Rosalina) et al.
RESEARCH ARTICLE Open Access
Multivariate joint modeling to identify
markers of growth and lung function
decline that predict cystic fibrosis
pulmonary exacerbation onset
E. R. Andrinopoulou1, J. P. Clancy2,3,4 and R. D. Szczesniak3,4,5*
Abstract
Background: Attenuated decreases in lung function can signal the onset of acute respiratory events known as
pulmonary exacerbations (PEs) in children and adolescents with cystic fibrosis (CF). Univariate joint modeling
facilitates dynamic risk prediction of PE onset and accounts for measurement error of the lung function marker.
However, CF is a multi-system disease and the extent to which simultaneously modeling growth and nutrition
markers improves PE predictive accuracy is unknown. Furthermore, it is unclear which routinely collected clinical
indicators of growth and nutrition in early life predict PE onset in CF.
Methods: Using a longitudinal cohort of 17,100 patients aged 6–20 years (US Cystic Fibrosis Foundation Patient
Registry; 2003–2015), we fit a univariate joint model of lung-function decline and PE onset and contrasted its
predictive performance with a class of multivariate joint models that included combinations of growth markers as
additional submodels. Outcomes were longitudinal lung function (forced expiratory volume in 1 s of % predicted),
percentiles of body mass index, weight-for-age and height-for-age and PE onset. Relevant demographic/clinical
covariates were included in submodels. We implemented a univariate joint model of lung function and time-to-PE
and four multivariate joint models including growth outcomes.
Results: All five joint models showed that declining lung function corresponded to slightly increased risk of PE
onset (hazard ratio from univariate joint model: 0.97, P < 0.0001), and all had reasonable predictive accuracy (cross-
validated area under the receiver-operator characteristic curve > 0.70). None of the growth markers alongside lung
function as outcomes in multivariate joint modeling appeared to have an association with hazard of PE. Jointly
modeling only lung function and PE onset yielded the most accurate (area under the receiver-operator
characteristic curve = 0.75) and precise (narrowest interquartile range) predictions. Dynamic predictions were
accurate across forecast horizons (0.5, 1 and 2 years) and precision improved with age.
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Conclusions: Including growth markers via multivariate joint models did not yield gains in prediction performance,
compared to a univariate joint model with lung function. Individualized dynamic predictions from joint modeling
could enhance physician monitoring of CF disease progression by providing PE risk assessment over a patient’s
clinical course.
Keywords: Dynamic prediction, Functional data analysis, Medical monitoring, Multivariate longitudinal data, Registry
analysis, Time-to-event
Background
Cystic fibrosis (CF) is a chronic lung disease in which
death commonly results from respiratory failure [1]. A
cycle of prolonged and acute drops in lung function
marks the clinical course of CF [2], most notably during
adolescence and early adulthood [3–5]. Forced expira-
tory volume in 1 s of % predicted (hereafter, FEV1), is
the primary surrogate of lung function and strongest
predictor of mortality in the CF population [6]. FEV1 re-
mains an important outcome in clinical trials and the
most relevant clinical indicator in monitoring lung func-
tion decline [7]. Fitting longitudinal FEV1 trajectories is
critical to understanding disease progression, but it can
be difficult to accurately depict the substantial variation
that this marker exhibits both between patients and
within an individual patient over time (Fig. 1). It is also
of clinical importance to identify an acute respiratory
event referred to as a pulmonary exacerbation (PE),
which frequently corresponds to sharp decreases in lung
function. Diagnosis of a PE depends on various factors
corresponding to lung function and nutritional status,
often resulting in a patient being hospitalized and ad-
ministered intravenous antibiotics [8]. Further, patients
who experience a PE often fail to recover to their corre-
sponding pre-event (i.e., “baseline”) levels of FEV1 [9].
For these reasons, it has been desirable in epidemiologic
studies to identify risk factors for having a PE.
Although maintaining lung function and minimiz-
ing risk of PEs are essential to survival, CF is a
multi-system disease in which malnutrition and poor
growth have been shown to adversely impact pul-
monary function [10]. Body mass index percentile
(BMIp) is the primary nutritional indicator in CF
[11]; guidelines published by the CF Foundation rec-
ommend maintaining BMIp >50th percentile [12]. A
recent CF registry analysis found that weight-for-age
(WFA) and height-for-age (HFA) percentiles more
accurately identify CF patients of poor nutritional
status and stunting, respectively, compared to BMI
percentiles [13].
Fig. 1 Lung function profiles over time. FEV1 (% predicted on the y-axis) is shown against time (age, in years, on the x-axis). Four representative
patients are shown with thicker and darker-shaded trajectories, while remaining patients’ trajectories are thinner and in light gray. Two of the
selected profiles (which appear lower overall, compared to the other two profiles) correspond to two individuals who experienced
pulmonary exacerbations
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These and other studies have collectively demon-
strated that multiple causes of disease progression are
typically observed from indicators of pulmonary and nu-
tritional decline, yet it remains unclear how the under-
lying longitudinal processes collectively evolve over time.
Joint modeling is a popular statistical approach used to
link longitudinal and time-to-event processes and is usu-
ally implemented through shared parameters [14]. These
models assume that the longitudinal and event processes
are correlated through random effects [15]. In particular,
we describe the evolution over time for the longitudinal
outcomes with a mixed-effects model. Then, we use
these estimated evolutions as time-varying covariates in
the survival model.
Novel applications of so-called univariate joint models
(refers to a single longitudinal marker being modeled
simultaneously with an event outcome) in CF epidemio-
logic studies have yielded new insights and predictions
regarding how changes in FEV1 are associated with
survival (i.e., time to death/lung transplant) [16–18].
Although these applications elucidate CF disease pro-
gression into its end stage, little is known about the util-
ity of joint models in assessing onset of PEs; these events
initialize earlier in life but could be attributable to down-
stream impacts. Furthermore, to our knowledge, the as-
sociation of one or more longitudinal outcomes with
onset of PE has not yet been addressed. Univariate joint
modeling potentially ignores the fact that different
markers of interest, specifically those related to growth
and nutrition status, could also have an influence on PE
in combination.
Due to computational advancements, such as new
software packages [19], joint models have enjoyed a re-
naissance in the last decade [20]. In this paper, we focus
on multiple longitudinal outcomes and their potential to
predict PE onset in children with CF. Specifically, we
propose a multivariate joint model of FEV1 and markers
of nutritional status with time-to-PE. The objective of
our study was to construct these models to estimate
how commonly collected markers of these longitudinal
processes evolve through the clinical course of CF, and
to compare results from these models regarding predict-
ive accuracy. We utilize data from the CFF patient regis-




The CF cohort for this empirical study consists of pa-
tients with longitudinal data recorded from childhood
until early adulthood (ages: 6–20 years) in the US Cystic
Fibrosis Foundation Patient Registry (CFFPR) between
January 1, 2003, and December 31, 2015. Patients youn-
ger than 6 years of age were excluded due to potentially
unreliable pulmonary function testing. To focus the
study on the most modern era of CF care, we considered
available data from 2003 onward. A detailed description
of this registry and its contents is provided elsewhere
[21].
Outcomes
To build the multivariate joint model for this cohort, we
focused on established outcomes of lung function and
nutrition. Outcomes on nutrition and growth, available
from the CFFPR and computed based on formulas from
the Centers for Disease Control and Prevention, in-
cluded the aforementioned percentiles for BMIp, WFA
and HFA. Observed FEV1 was expressed as percentage
of predicted using established reference equations for
age, sex and race [22, 23]. Occurrence of first PE, the
event outcome, was subject to censoring and considered
to have occurred if documented in the CFFPR as war-
ranting treatment with intravenous antibiotics in the
hospital.
Covariates
Covariates from the aforementioned literature were con-
sidered, as well as findings from analyses specified in the
most recent CFFPR report. These included genotype
(F508del homozygous, heterozygous or neither/un-
known), sex, Hispanic ethnicity, socioeconomic status
(SES, having only state/federal or no insurance was re-
corded as 1, and 0 otherwise); time-varying covariates
included use of pancreatic enzymes (corresponding to
pancreatic insufficiency), CF-related diabetes (CFRD,
with or without fasting hyperglycemia), positive cultures
for methicillin-resistant Staphylococcus aureus (MRSA)
and Pseudomonas aeruginosa (Pa).
Baseline was defined as the time at which all longitu-
dinal outcomes were first recorded during the eligibility
period. A birth cohort variable was used to account for
potential delayed entry into the registry and changes due
to advancements in CF care and therapeutics approvals.
Another time-varying covariate was used to account for
irregular sampling bias, potentially induced by patients
having a varying number of clinical encounters over
time; for a given patient and encounter, this variable was
the total number of encounters within the prior year.
Data acquired after lung transplant were excluded.
Descriptive analysis
Descriptive statistics, including median (Q1-Q3) for con-
tinuous variables and n (%) for categorical variables,
were used to summarize cohort characteristics and ex-
tent of follow-up available for each patient.
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Joint model setup and notation
Prior to multivariate joint modeling, we performed a
univariate joint model that included only FEV1 and
time-to-first PE. To model the association between com-
binations of longitudinal FEV1 and other outcomes to-
gether with time-to-first PE, we examined multivariate
joint models. We describe the notation using a particular
multivariate joint model with two longitudinal outcomes,
which can be generalized to the case of three outcomes
(e.g. FEV1, WFA and HFA). We assume y1i(t) and y2i(t)
to be the follow-up measurements (e.g., FEV1 and BMIp,
respectively) for patient i (i = 1, …, n) at a specific time
point t. We follow the framework of mixed-effects
models to model the longitudinal outcomes:
y1i tð Þ ¼ xT1i tð Þβ1 þ zT1i tð Þb1i þ ε1i tð Þ ¼ m1i tð Þ þ ε1i tð Þ
and
y2i tð Þ ¼ xT2i tð Þβ2 þ zT2i tð Þb2i þ ε2i tð Þ ¼ m2i tð Þ þ ε2i tð Þ;
where xT1iðtÞ and xT2iðtÞ denote the design vectors for the
fixed effects regression coefficients β1 and β2. Moreover,
zT1iðtÞ and zT2iðtÞ denote the design vectors for the ran-
dom effects b2i and b1i. We included natural cubic
splines to accommodate nonlinear progression of differ-
ent covariate levels over age with respect to each longi-
tudinal outcome, using an approach similar to our
previous work in modeling nonlinear age-related FEV1
[5]) [24]). Furthermore, the longitudinal outcomes FEV1
and BMIp are correlated through the random effects bi =
{b1i, b2i}, where a multivariate normal distribution is
assumed.
For the PE part, we assume Ti to be the observed fail-
ure time for patient i, as Ti ¼ minðT i ;CiÞ where T i in-
dicates the true failure time of individual ith
experiencing the event (occurrence of PE) and Ci the
censored time. We assume a proportional hazard model
for the risk of the event:
hiðtÞ ¼ h0ðtÞexpfωTi γþ a1m1iðtÞ þ a2m2iðtÞg;
where ωTi denotes row vectors of the design matrix of
the baseline covariates ,γ is the corresponding regression
coefficients vector, and a1 and a2 are the coefficients
that connect the longitudinal and event processes. In
our case, these parameters represent the strength of the
association between FEV1 and BMIp with onset of PE.
To better understand the connection between the event
and longitudinal parts in our model, we explain the
meaning of the a1 and a2 parameters. Specifically, for a
one unit increase in the underlying value of FEV1 for pa-
tient i, the hazard ratio is exp(a1) assuming that the
baseline covariates and BMIp remain the same. Similarly,
exp(a2) is the hazard ratio when the underlying value of
BMIp for the i -th patient is increased by one unit
assuming that the baseline covariates and FEV1 remain
the same.
Implementation
We employed Markov-Chain Monte-Carlo (MCMC) via
Gibbs sampling using the ‘JMbayes’ package (Version
0.8–82) in R (Version 3.5.3., R Foundation for Statistical
Computing, Vienna Austria) to obtain the parameters
from the respective posterior distributions under the
multivariate joint model [19]. The highest posterior
density (HPD) and accompanying standard errors were
used to estimate each parameter of interest. Due to the
large patient sample size that led to memory problems,
we randomly divided the dataset into three parts (each
part had similar percentage of PE at onset). Each of the
datasets was fitted separately, and for the final results we
combined the MCMC samples as described previously
[25]. Code implementation is provided as supplemental
material. In total, we fit five joint models wherein PE on-
set was the event: i) only FEV1; others included ii) BMIp;
iii) HFA; iv) WFA; v) WFA and HFA. The multivariate
joint models in (ii) – (iv) were implemented to evaluate
the impact of different measures of nutritional status on
predicting PE onset. Due to the large number of parame-
ters in scenario (v), we assumed a less flexible evolution
for FEV1 and BMIp over time. In particular, we postulate
natural cubic splines with two degrees of freedom to es-
timate this evolution instead of natural cubic splines
with three degrees of freedom assumed in the other
scenarios.
Evaluating predictive performance
We calculated the area under the receiver-operator char-
acteristic curve (AUC) to evaluate predictive accuracy of
each model with respect to PE events using ten-fold
cross validation. A large value of AUC indicates the pre-
ferred model. To obtain correct estimates of the AUC
we performed a 5-fold cross validation procedure,
wherein each time we selected 700 individuals from the
large data set and we split it in five subsets. Each time
we fitted the model in four of the subsets, we calculated
the AUC in the subset that was excluded. The calcula-
tion of the AUC was performed at 12 and 16 years of
age with prediction windows of 0.5, 1, 2 years, in order
to mimic clinically meaningful age strata and prediction
windows. This procedure was repeated 100 times. Ap-
propriate diagnostics for joint models were examined.




There were 16,455 patients contributing 245,513 obser-
vations to the analysis cohort (Table 1). Patients who
Andrinopoulou et al. BMC Pulmonary Medicine          (2020) 20:142 Page 4 of 11
had a PE during follow-up tended to be female and had
the F508del homozygous genotype. They had slightly
higher proportions of infections with MRSA and Pa than
patients who did not have a PE during follow up. By
contrast, patients who were PE-free during follow-up
had a higher reported use of pancreatic enzymes and
had higher levels of lung function and better nutrition
status at baseline. Extent of follow-up also differed ac-
cording to PE onset. Representative trends of lung func-
tion decline according to PE status are shown in Fig. 1
and reflect summary results from Table 1. Median (95%
CI) age of PE onset was 19.5 (19.3–19.6) years (Fig. 2).
Joint model estimates
Each Gibbs sampler ran for 900 iterations, and the first
600 iterations were discarded for burn-in. Shared param-
eter estimates, which represent associations between
each longitudinal process and the PE event, are shown
for all five fitted joint models (Table 2). The log-hazard
estimates of the shared parameters, which were intro-
duced in Section 3.2, indicate that FEV1 was consistently
and negatively associated with PE onset. Corresponding
hazard ratio estimates ranged from 0.96 to 0.97, suggest-
ing a small association between changes in the FEV1 tra-
jectory and PE onset. Jointly modeling BMIp, WFA or
HFA as shown in respective models (ii) – (iv) did not
impact association between FEV1 and PE onset, and
their associations with PE onset did not reach statistical
significance.
The univariate joint model (i) in Table S1 indicated
that being Hispanic and having lower SES, MRSA and
CFRD and using pancreatic enzymes corresponded to
worse overall FEV1. There were nonlinear associations,
as reflected by spline coefficients, between each of geno-
type, sex, SES, MRSA, Pa and CFRD and FEV1 decline.
In the PE event submodel, patients who were male, used
pancreatic enzymes, had lower SES, infection with
MRSA and Pa and were diagnosed with CFRD had
Table 1 Cohort characteristics according to PE onset*
Characteristic at Baseline Had PE during follow up (n = 5510) PE-free during follow up (n = 10,945) Overall (n = 16,455)
Genotype^
Homozygous 53.0% 45.6% 48.1%
Heterozygous 36.4% 39.1% 38.2%
None/unknown 10.6% 15.3% 13.7%
Male sex^ 47.4% 53.7% 51.6%
Hispanic 9.2% 8.5% 8.7%
Birth cohort^
< 1981 16.7% 19.8% 18.8%
1981–1989 31.6% 22.2% 25.3%
1990–1994 22.0% 13.9% 16.6%
1995–1999 24.6% 26.9% 26.1%
> 1999 5.1% 17.2% 13.2%
Age at entry, years^ 8.7 (6.2–13.0) 7.9 (6.2–14.0) 8.2 (6.2–13.6)
Low SES 54.0% 52.4% 49.8%
MRSA^ 9.5% 6.4% 7.4%
Pa^ 24.2% 17.3% 19.6%
CFRD^ 5.1% 3.2% 3.9%
Pancreatic insufficient^ 32.3% 42.3% 39.0%
FEV1, % predicted^ 83.8 (67.3–98.0) 93.5 (79.3–105.2) 90.6 (74.9–103.2)
BMIp, percentile^ 43.1 (19.9–67.0) 51.1 (27.3–73.4) 48.6 (24.8–71.3)
WFA, percentile^ 29.1 (10.2–55.0) 38.9 (16.7–64.7) 35.5 (14.3–61.7)
HFA, percentile^ 24.5 (8.4–49.8) 32.4 (12.3–59.5) 29.7 (10.7–56.7)
Length of follow up, years^ 1.9 (0.5–4.4) 3.1 (1.0–6.3) 2.6 (0.8–5.7)
Alive^ 99.9% 99.7% 99.8%
Abbreviations: BMIp body mass index percentile, CFRD cystic fibrosis related diabetes, FEV1 forced expiratory volume in 1 s, HFA height for age, MRSA methicillin-
resistant Staphylococcus aureus, Pa Pseudomonas aeruginosa, PE pulmonary exacerbation, SES socioeconomic status, WFA weight for age. * Values at first recorded
entry in the database are used for all patients except for follow-up and death; results for continuous and categorical variables are expressed as median (Q1-Q3)
and % over column total, respectively. Characteristics marked as ^ imply P < 0.05 for comparison between PE and PE-free groups. Between-group frequencies
compared using Chi-square test of independence; continuous variables compared between groups using Welch two-sample t-test
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greater risk of PE onset. The multivariate joint models,
each of which included a longitudinal submodel for FEV1,
had similar association results for the clinical/demo-
graphic covariates and shared parameters regarding FEV1.
The multivariate joint model (ii) in Table S2, which in-
cluded a longitudinal submodel for BMIp, showed that
being born into an older birth cohort, taking pancreatic
enzymes and having more frequent clinic visits corre-
sponded to higher BMIp. There were nonlinear associa-
tions between each of genotype, SES, birth cohort and
Pa with BMIp trajectory. In Table S3, using height in
multivariate joint model (iii), we found that having a
F508del homozygous genotype and belonging to an
older birth cohort were positively associated with overall
HFA. By contrast to the BMIp submodel, having more
frequent clinic visits corresponded to lower HFA. Similar
nonlinear associations were observed in the BMIp and
HFA submodels. Results for the WFA submodel in (iv)
were also similar (Table S4). The multivariate joint
model in (v), compared to models (iii) and (iv), had
slight changes in associations shown in the WFA sub-
model; however, the HFA submodels were similar.
Fig. 2 Kaplan-Meier plot of time to first recorded pulmonary exacerbation. Time is expressed as age (in years on the x-axis) and PE-free survival
probability (y-axis) corresponds to probability of not experiencing a pulmonary exacerbation. Data shown include all patients
Table 2 Associations between longitudinal processes and risk of PE*
log (HR) estimates (SE) and P-value
Joint Model FEV1 BMIp WFA HFA
I – Null −0.0305 (5e-04) P < 0.001 – – –
II – BMIp −0.0324 (6–04) P = 0.002 − 0.0004 (3–04) P = 0.988 – –
III – WFA −0.0334 (7e-04) P = 0.003 – 0.0006 (2e-04) P = 0.761 –
IV – HFA −0.0308 (5e-04) P = 0.001 – – 0.0004 (1e-04) P = 0.927
V – WFA and HFA −0.0327 (6 e-04) P = 0.005 – 0.0022 (9e-04) P = 0.683 −0.0019 (1e-03) P = 0.737
Abbreviations: BMIp body mass index percentile, FEV1 forced expiratory volume in 1 s, HFA height-for-age percentile, HR hazard ratio, PE pulmonary exacerbation,
WFA weight-for-age percentile. *Associations estimated as log hazard using the posterior mean (SE) with corresponding p-value in the Bayesian sense. Log-hazard
estimates > 0 (< 0) imply positive (negative) association between the longitudinal process and PE onset. Results are reported as HRs in text. Each model includes
all covariates (see Methods). All joint model parameter estimates are provided in Supplement S1
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Predictive performance
The results of the predictive performance of the joint
models presented in Table 2 are summarized in Fig. 3.
In particular, the AUC of each model is presented as-
suming a different prediction interval (0.5, 1 and 2
years), which starts at adolescence or early adulthood
(ages 12 and 16 years, respectively). The median AUC
values ranged from 0.7 to 0.8. Moreover, the univariate
joint model, assuming only FEV1, provided the highest
AUC value and was most robust across age strata and
prediction windows. Precision of the predictions was
assessed by examining the interquartile ranges of the
boxplots in Fig. 3. Precision was lower for predictions
done at adolescence, regardless of the interval, compared
to precision estimated during young adulthood. Preci-
sion was highest under the univariate joint model for
predicting PE risk at age 16 years out to 2 years. In terms
of overall precision, the multivariate joint models per-
formed similarly well.
Dynamic predictions for an individual CF F508del
homozygous patient (born 1990–1994) are shown in
Fig. 4 for the multivariate joint model of longitudinal
FEV1 and BMIp. Her first recorded FEV1 and BMIp
were 98.5% predicted and at the 48.2 percentile, respect-
ively. She began taking pancreatic enzymes and had a
positive culture for Pa around 10 years old. Her moni-
tored outcomes are depicted across four clinic visits
from ages 8.2 to 14.3 years, along with probability of not
having a PE over follow up. Her long-term risk of PE ap-
pears higher during an earlier visit (e.g., PE-free prob-
ability is 0.6), compared to later visits that are informed
by dynamic predictions from the multivariate joint
models (e.g., PE-free probability increased to 0.8). Com-
mensurate with these results are the changes in her
FEV1 and BMIp trajectories, which imply minimal rate
of decline and improving nutritional status, respectively.
She did not experience a PE event during follow up. Her
projected PE-free probabilities over follow up using a
multivariate joint model replacing BMIp with WFA and
HFA were similar (Fig. 5); however, precision with which
PE-free probability could be estimated was decreased
using this combination of markers rather than BMIp.
Discussion
Past epidemiologic studies of PE onset have largely fo-
cused on explanation of risk factors rather than identify-
ing predictors of this event. Clinical consensus on PE
symptoms is lacking. Acute drops in lung function and
changes in nutritional status have been recognized as
key determinants [26]; however, relative contributions of
these markers to prediction of PE onset have not been
studied. Further, markers of growth/nutritional status
(WFA, HFA and BMIp) and lung function (FEV1) are
endogenous variables. In this epidemiologic study, we
assessed predictive performance of these markers using
a series of joint models. Our novel application confirmed
the reliance of changes in the FEV1 trajectory on pre-
dicting PE events but revealed the clinical utility that
these novel models could have for monitoring multiple
indicators of disease progression for an individual pa-
tient. In parallel, our application highlights that, al-
though pancreatic enzyme use is commonly employed as
Fig. 3 Cross-validation metrics from joint model. Results summarized as box plots show ability of each joint model to predict pulmonary
exacerbation onset as estimated by area under the curve (AUC, y-axis), stratified by age and forecast horizons (x-axis)
Andrinopoulou et al. BMC Pulmonary Medicine          (2020) 20:142 Page 7 of 11
a marker of pancreatic insufficiency, their use was asso-
ciated with lower PE frequency over follow-up (Table 1).
It is possible that pancreatic enzyme use is also a marker
of receiving higher-quality healthcare.
We found that the univariate joint model, which uti-
lized FEV1 and PE event submodels without accounting
for growth/nutritional status, produced the most accur-
ate and precise predictions of all models considered. In
addition, these predictions were largely robust across a
range of age and prediction window strata. A potential
reason for this finding is that the diagnosis of PE events
may rely more heavily upon acute changes in lung func-
tion than changes in nutritional status. Changes in
growth are relatively slow over time, compared to pre-
cipitous drops in lung function, which could be respon-
sible for the lack of improved predictive performance
when adding WFA, HFA or BMIp. Of the three markers
available from the CFFPR to study growth/nutritional
status, it is plausible that BMIp would be most likely to
improve prediction of PE onset (after including FEV1);
however, it appears that including BMIp as a submodel
introduces additional noise into the joint modeling of
these processes, thereby making predictions less accurate
and more variable (Fig. 3). In addition, associations be-
tween clinical/demographic covariates and each outcome
were largely consistent across FEV1 submodels. This
finding further suggests that WFA, HFA and BMIp do
not play a large role in clinical diagnosis of PE; however,
the findings from the study aimed at prediction cannot
serve as a substitute for assessing the causal effects of
nutrition [27]. The results do warrant further investiga-
tion of a causal model examining the extent to which
nutrition and growth mediate the relationship between
lung function and PE onset. Understanding these causal
underpinnings are a separate but important area of fu-
ture work.
The multivariate joint models afforded the opportunity
to obtain dynamic predictions at the individual patient
level (Fig. 4); however, using multiple nutrition markers
may decrease precision of PE predictions (Fig. 5). The
decrease in precision may be due to relatively large vari-
ability in each outcome both between patients and
within individual patients over time. Both Figs. 4 and 5
illustrate the substantial intra-individual variability in
Fig. 4 Observed and predicted evolution of markers of lung function and growth. Lung function (FEV1% predicted, upper left y-axis) and growth
(BMIp, lower left y-axis) and probability of not having a pulmonary exacerbation (PE-free probability, upper/lower right y-axis) in a female CF
F508del homozygous patient over a series of four clinical encounters (observations are black dots; mean response is black curve). Arrows illustrate
how her probability of remaining PE-free is dynamically updated with each clinical encounter
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each of the lung function and growth markers. In con-
trast with joint modeling results, we found that patients
who experienced a PE tended to have lower WFA, HFA
and BMIp, as well as lower FEV1 (Table 1). If changes in
nutrition markers are less influential in making a PE
diagnosis than change in lung function, the contrasting
results could reflect differences between association and
prediction [27]. All of the outcome markers could be as-
sociated with PE onset but not all markers may be ne-
cessary to accurately predict it. The focus of the
manuscript was to investigate the predictive perform-
ance of the different joint models. Hence, we did not as-
sess the fit of those models. Using these dynamic
predictions revealed the heterogeneous nature of CF dis-
ease progression but also highlighted the benefit of up-
dated predictions across clinic visits. The ability to
simultaneously monitor multiple markers of disease pro-
gression, which may serve as a clinical decision support
tool, provides an advantage of the multivariate joint
model over the univariate joint model and the more
conventional Cox model. An area of future study could
be the additional consideration of other markers of lung
function as predictors, including forced vital capacity
(FVC), the FEV1/FVC ratio and forced expiratory flow at
25–75% (referred to as FEF25–75). Furthermore, in this
research we assumed the underlying value of the
Fig. 5 Multivariate joint model predictions with other growth markers. Same female CF patient as in Fig. 4, but simultaneously modeling lung
function (FEV1, upper-left y-axis), growth as weight-for-age (WFA, middle-left y-axis) height-for-age (HFA, lower-left y-axis) percentiles and
probability of not having a pulmonary exacerbation (PE-free probability, repeated along the right y-axis). Her probability of remaining PE-free is
similar to Fig. 4 but estimates are less precise based on 95% CI over the four clinical encounters
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biomarkers (FEV1, WFA, HFA and BMIp) to be associated
with PE. A special feature of these biomarkers is that they
are time-dependent, therefore the assumption of the under-
lying value might be too strict. Future research could focus
on investigating whether other structures, such as the slope
of these markers, could provide a stronger association with
PE and a better predictive performance.
A limitation of this study is that the models cannot be used
to draw conclusions about recurrent PE events, since the PE
event submodel estimates time-to-first PE. Although this
focus simplifies analyses, time-to-first PE during follow up
tended to occur in early adulthood (Fig. 2). It is possible that
a portion of patients experienced a PE prior to follow-up
available in the data (e.g., patients born in older birth co-
horts). In addition, the advent of newer therapies and/or
quality improvement initiatives likely increase the overall tra-
jectories of outcomes studied. We accounted for these poten-
tial sources of bias by including levels of birth cohort
through linear and nonlinear terms in each of the longitu-
dinal submodels (Tables S1-S5). Consequently, including
higher-order associations through splines required additional
degrees of freedom. Future work is needed on covariate se-
lection strategies in the context of multivariate joint models
[28, 29]. Fitting these more complex models to a large num-
ber of patients followed over long periods of time creates a
computational challenge. We addressed this issue by parti-
tioning into distinct sets of patients, which was the only feas-
ible manner to estimate the model parameters; however, the
bootstrap approach that we employed does not account for
all the variability of the outcomes. Lastly, the multivariate
joint models presented here allow for different patterns of
missing data among the longitudinal outcomes but assume
that the missingness is conditional on observed data only
(i.e., missing at random), specifically occurrence of PE. It is
possible that missingness could be related to patient severity.
A recent study demonstrates that linear mixed effects model-
ing, which is the framework for the longitudinal submodels
used in this application, can alleviate this potential source of
bias [30].
Conclusion
The univariate joint modeling of the CFFPR demon-
strates the reliance of PE diagnosis on FEV1, and multi-
variate joint modeling of FEV1 and other outcomes
related to nutritional status and growth can be used for
routine medical monitoring of an individual patient and
dynamic assessment of PE risk over time.
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